Healthy individuals were randomised to either receive Dengue TcP using an intradermal microneedle injection or a comparator. Credit: Jarun Ontakrai/Shutterstock.com.

Emergex Vaccines has reported positive outcomes from the naNO-DENGUE Phase I trial of DengueTcP, a T cell-priming immune set-point candidate designed for treating dengue.

Evaluating the tolerability, safety, and reactogenicity of 2.5nmol and 7.5nmol total peptide doses of DengueTcP in healthy volunteers is the primary objective of the dose-finding, randomised, vehicle-controlled, double-blind study.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

A total of 26 healthy individuals aged 18-45 years were randomised to either receive Dengue TcP using an intradermal microneedle injection, or a comparator.

Participants were enrolled at the Centre for Primary Care and Public Health in Lausanne, Switzerland.

Both dosages were well tolerated and safe with no treatment-related serious adverse events observed.

See Also:

The absence of anti-DENV antibodies, a favourable outcome that reduces the antibody-dependent enhancement risk of the disease, was also observed during the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Participants were followed over a six-month period after the first injection.

Emergex chief medical officer Dr Athanasios Papadopoulos said: “These data demonstrate that our product platform has an acceptable safety profile and successfully mobilises viral-specific CD8+ T cells, which may elicit broad and long-term immune memory.

“Showing that we can increase the T cell-based immunity without affecting the antibodies means that we can improve any previous immune status of a person.

“This trial is the first time that a regulator has approved an assessment of a T cell-priming set-point candidate against infectious diseases for clinical use based solely on a T cell response; thus, we are delighted that the trial was successful.”